Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2010075635) COMBINATION THERAPIES USING NAP
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2010/075635 International Application No.: PCT/CA2009/001906
Publication Date: 08.07.2010 International Filing Date: 30.12.2009
IPC:
A61K 38/08 (2006.01) ,A61K 31/496 (2006.01) ,A61K 31/519 (2006.01) ,A61K 31/551 (2006.01) ,A61K 31/5513 (2006.01) ,A61K 31/554 (2006.01) ,A61K 38/02 (2006.01) ,A61K 38/10 (2006.01) ,A61K 38/16 (2006.01) ,A61K 38/17 (2006.01) ,A61P 25/18 (2006.01) ,A61P 25/28 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08
Peptides having 5 to 11 amino acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
551
having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
551
having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
5513
1,4-Benzodiazepines, e.g. diazepam
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
554
having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
02
Peptides of undefined number of amino acids; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
10
Peptides having 12 to 20 amino acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
18
Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
28
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applicants:
RAMOT AT TEL AVIV UNIVERSITY LTD. [IL/IL]; P. O. Box 39296 TeI Aviv 61392, IL (AllExceptUS)
ALLON THERAPEUTICS INC. [CA/CA]; CA (AllExceptUS)
GOZES, lllana [IL/IL]; IL (UsOnly)
MCCAULEY, Gordon [CA/CA]; CA (UsOnly)
Inventors:
GOZES, lllana; IL
MCCAULEY, Gordon; CA
Agent:
TAYLOR, Euan R.; Suite 2800 Park Place 666 Burrard Street Vancouver, BC V6C 2Z7, CA
Priority Data:
61/141,58830.12.2008US
Title (EN) COMBINATION THERAPIES USING NAP
(FR) POLYTHÉRAPIES UTILISANT LE NAP
Abstract:
(EN) This invention relates to treatment of neurodegeneration, multiple sclerosis, or schizophrenia using an ADNF III polypeptide in combination with another therapeutic agent. Neurodegeneration, including neurodegeneration caused by dementia-related conditions, such as tauopathies, including Alzheimer's disease, and aging-related dementia, is treated by a combination of an ADNF III polypeptide and an acetylcholinesterase inhibitor. Multiple sclerosis is treated by a combination of an ADNF III polypeptide and glatiramer acetate. Schizophrenia is treated with a combination of an ADNF III peptide and an antipsychotic drug, selected from Aripiprazole, Clozapine, Ziprasidone, Resperidone, Quetiapine, and Olanzapine.
(FR) La présente invention concerne le traitement de la neurodégénérescence, de la sclérose en plaques, ou de la schizophrénie à l'aide d'un polypeptide ADNF III en combinaison avec un autre agent thérapeutique. La neurodégénérescence, y compris la neurodégénérescence provoquée par des conditions liées à la démence, telles que les tauopathies, comprenant la maladie d'Alzheimer, et la démence liée à l'âge, est traitée par une combinaison d'un polypeptide ADNF III et d'un inhibiteur de l'acétylcholinestérase. La sclérose en plaque est traitée par une combinaison d'un polypeptide ADNF III et d'acétate de glatiramère. La schizophrénie est traitée avec une combinaison d'un peptide ADNF III et d'un médicament antipsychotique, choisi parmi l'aripiprazole, la clozapine, la ziprasidone, la respéridone, la quétiapine, et l'olanzapine.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP2381955JP2012514011